Markets:

Overview

News

Currencies

International

Treasuries

Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

235.41 +5.78 (+2.51%)

Streaming Delayed Price Updated: 10:15 AM EDT, Jun 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Jazz Pharmaceuticals plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

Jazz Pharma's Zepzelca Combo Shows Survival Edge In Lung Cancer Study ↗

June 03, 2025

Jazz Pharma's Zepzelca plus Tecentriq significantly improved survival in a Phase 3 study for extensive-stage small-cell lung cancer patients.

Via Benzinga

The Analyst Verdict: Jazz Pharmaceuticals In The Eyes Of 11 Experts ↗

June 03, 2025

Via Benzinga

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) – An Undervalued Biopharmaceutical Stock Worth Watching ↗

May 22, 2025

Jazz Pharmaceuticals (NASDAQ:JAZZ) appears undervalued with strong profitability and reasonable growth, making it a potential pick for value investors.

Via Chartmill

JAZZ Q1 Earnings Call: Revenue and Profit Miss, Product Pipeline Drives Outlook

May 19, 2025

Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) fell short of the market’s revenue expectations in Q1 CY2025, with sales flat year on year at $897.8 million. On the other hand, the company’s...

Via StockStory

Topics World Trade

Pharmaceuticals Stocks Q1 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers

May 13, 2025

As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the pharmaceuticals industry, including Jazz Pharmaceuticals (NASDAQ:JAZZ) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

Earnings Scheduled For May 6, 2025 ↗

May 06, 2025

Via Benzinga

Preview: Jazz Pharmaceuticals's Earnings ↗

May 05, 2025

Via Benzinga

Jazz Pharmaceuticals (NASDAQ:JAZZ) Misses Q1 Sales Targets

May 06, 2025

Via StockStory

Earnings To Watch: Jazz Pharmaceuticals (JAZZ) Reports Q1 Results Tomorrow

May 05, 2025

Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) will be reporting results tomorrow after market close. Here’s what to expect.

Via StockStory

Topics Artificial Intelligence

Jazz Pharmaceuticals (JAZZ) Reports Earnings Tomorrow: What To Expect

May 05, 2025

Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) will be reporting earnings tomorrow afternoon. Here’s what to look for.

Via StockStory

Despite its impressive fundamentals,JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) remains undervalued. ↗

May 01, 2025

When you look at JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.

Via Chartmill

A Glimpse Into The Expert Outlook On Jazz Pharmaceuticals Through 12 Analysts ↗

March 05, 2025

Via Benzinga

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ): A Potential Undervalued Stock ↗

May 01, 2025

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ): A Potential Undervalued Stock

Via Chartmill

3 Reasons to Sell JAZZ and 1 Stock to Buy Instead

April 28, 2025

Jazz Pharmaceuticals currently trades at $109.85 per share and has shown little upside over the past six months, posting a small loss of 1.4%.

Via StockStory

3 Small-Cap Stocks in the Doghouse

April 23, 2025

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a...

Via StockStory

Pharmaceuticals Stocks Q4 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers

April 17, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Jazz Pharmaceuticals (NASDAQ:JAZZ) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

Where Jazz Pharmaceuticals Stands With Analysts ↗

April 10, 2025

Via Benzinga

3 Value Stocks Skating on Thin Ice

March 19, 2025

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are...

Via StockStory

Q4 Earnings Roundup: Elanco (NYSE:ELAN) And The Rest Of The Pharmaceuticals Segment

March 18, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how pharmaceuticals stocks fared in Q4, starting with Elanco...

Via StockStory

Topics Artificial Intelligence Intellectual Property

For those who appreciate value investing, JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) is a compelling option with its solid fundamentals. ↗

March 15, 2025

JAZZ PHARMACEUTICALS PLC is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:JAZZ showcases decent financial health and profitability, coupled with an attractive price.

Via Chartmill

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 2seventy bio, Inc. (Nasdaq - TSVT), Bridge Investment Group Holdings Inc. (NYSE - BRDG), Chimerix, Inc. (Nasdaq - CMRX), 180 Degree Capital Corp. (Nasdaq – TURN)

March 11, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

DraftKings To Rally Over 29%? Here Are 10 Top Analyst Forecasts For Monday ↗

March 10, 2025

Via Benzinga

Cancer-Focused Zymeworks' Q4 Earnings Miss Expectations, Reprioritize Resources To Focus On ZW251 ↗

March 06, 2025

Zymeworks shifts focus to ZW251 for liver cancer, delaying ZW220. Q4 revenue and earnings missed estimates. GSK milestone adds $14M to cash reserves.

Via Benzinga

Topics Earnings

3 Highly Ranked Medical Stocks To Buy Amid Recent Market Volatility: JAZZ, OPCH, PCRX ↗

March 05, 2025

The medical sector is usually of interest during economic uncertainty, especially when it leads to heightened stock market volatility.

Via Talk Markets

Topics Stocks / Equities

Jazz Pharma To Buy Chimerix For $935 Million, Strengthening Rare Cancer Pipeline ↗

March 05, 2025

Jazz Pharmaceuticals will add dordaviprone, a potential treatment for a rare brain tumor, to its growing oncology pipeline.

Via Benzinga

Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio

March 05, 2025

From Chimerix, Inc.; Jazz Pharmaceuticals plc

Via GlobeNewswire

Novartis Earns Near-Best Overall Rating As Profit Growth Climbs ↗

March 05, 2025

Novartis ranks No. 1 among in the 33-stock Medical-Ethical Drugs industry group. Novartis got a Composite Rating upgrade to 96 on Wednesday.

Via Investor's Business Daily

3 Small-Cap Stocks Skating on Thin Ice

March 04, 2025

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside...

Via StockStory

CrowdStrike To Rally Over 18%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

February 26, 2025

Via Benzinga

Earnings To Watch: Amphastar Pharmaceuticals (AMPH) Reports Q4 Results Tomorrow

February 26, 2025

Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) will be reporting earnings tomorrow after market hours. Here’s what to expect.

Via StockStory

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.